Oyster Point Pharma Scores $93 Million Series B to Focus Its Gaze on Dry Eye Disease

Retrieved on: 2019-02-25 23:22:30

Tags for this article:

Medicine

RTT

Click the tags to see associated articles and topics

Oyster Point Pharma Scores $93 Million Series B to Focus Its Gaze on Dry Eye Disease. View article details on hiswai:

Excerpt

<div>Existing investors <b>New Enterprise Associates</b> (NEA)and Versant Ventures participated, as well as new investor Vida Ventures. The company plans to ...</div>

Article found on:

View Original Article